QUOTE AND NEWS
Motley Fool  Oct 6  Comment 
Medivation stock is up more than 1,000% over the past three years and yet is still considered a cheap stock when using this Wall Street metric. Find out why Wall Street has fallen in love with Medivation, and whether or not the stock can head higher.
TheStreet.com  Sep 24  Comment 
NEW YORK (TheStreet) -- Shares of Medivation Inc. are down today 0.43% to $98.17aafter the company was downgraded to "neutral" from "buy" at Goldman Sachs. Goldman lowered the San Francisco-based biopharmaceutical company's ratings based on a...
SeekingAlpha  Sep 24  Comment 
By ONeil Trader: Medivation (NASDAQ:MDVN) has been among the top performing biotech stocks since bottoming in late April 2014. The company is benefiting from strong sales of its only drug Xtandi, as revenue grew significantly since the drug's...
TheStreet.com  Sep 24  Comment 
NEW YORK (TheStreet) -- RATINGS CHANGES FTI Consulting was upgraded at William Blair to outperform from market perform. Management is making solid progress on turning the business around, William Blair said. Goldcorp was upgraded at Credit...
Benzinga  Sep 24  Comment 
Analysts at Goldman Sachs downgraded Medivation (NASDAQ: MDVN) from Buy to Neutral. The target price for Medivation has been raised from $90 to $110. Medivation shares have jumped 70.25% over the past 52 weeks, while the S&P 500 index has...
Benzinga  Sep 24  Comment 
TheStreet.com  Sep 18  Comment 
NEW YORK (TheStreet) -- RATINGS CHANGES Adobe was downgraded to hold at TheStreet Ratings. You can view the full analysis from the report here: ADBE Ratings Report Full Circle Capital was downgraded to sell at TheStreet Ratings. You can view...
SeekingAlpha  Sep 16  Comment 
By Kanak Kanti De: Medivation Inc. (NASDAQ:MDVN) last week received an approval from the U.S. FDA for expanded use of Xtandi®. Previously approved for patients with metastatic castration-resistant prostate cancer or metastatic CRPC who received...
StreetInsider.com  Sep 15  Comment 
The following is a list of notable articles to help get you through the lunch hour: ReWalk Robotics (RWLK) Gets 'Bubblicious'; Now Best Performing IPO of 2014 -> Read this! USA Technologies, Inc. (USAT) Hits Session Highs; Mentioned Positively...
Benzinga  Sep 13  Comment 
CNBC Fast Money's Joe Terranova said on "Fast Money Halftime Report Final Trade" that he is a buyer of Medivation (NASDAQ: MDVN), which fell 1.28 percent on Friday. Pete Najarian thinks that Citigroup (NYSE: C) is going to breakout to the...
SeekingAlpha  Sep 12  Comment 
By Mrs. BullBear: In August 2012 biotech firm Medivation (NASDAQ:MDVN) launched prostate cancer drug Xtandi. Since this launch XTANDI has trailed it's competitor in the anti-androgen market, Johnson & Johnson (NYSE:JNJ) produced Zytiga, due to a...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki